CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors — Stella

Home/Stage IV Ovarian Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Stage IV Ovarian Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Phase

Early testing

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Enrollment target

~200 participants

Started

June 2022

Primary completion

June 2030

Age range

18 Years – 75 Years

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.